2024 Guardian Annual Symposium
Join us on May 9 & 10, 2024 from 11:00-2:30pm EST each day for a 3-hour Zoom webinar focused on a clinical refresher on many topics that impact health professionals practicing in the long term care setting. The program provides three hours EACH DAY of continuing education for general pharmacists, consultant pharmacists*, nurses and administrators. (Accreditation has been approved through NAB, ACPE and CE Broker). Registration is required.
(*This webinar provides the FL CPh recertification credit.)
Schedule at a Glance
Thursday, May 9:
11:00am to 12:00pm Session 1 “Safety in Numbers” Speaker, Chad Worz, PharmD
12:00pm to 12:10pm Break
12:10pm to 1:10pm Session 2 “Levodopa and Beyond – Advances in the Treatment of Parkinson’s Disease” Speaker, Dana Saffel, PharmD
1:10pm to 1:20pm Break
1:20pm to 2:20pm Session 3 “Addressing the Expanding Use of Psychotropic Medications in Long-Term Care Settings” Speaker, Darla Spears, PharmD
Friday, May 10:
11:00am to 12:00pm Session 1 “Drug Diversion” Speaker James Almond, DEA
12:00pm to 12:10pm Break
12:10pm to 1:10pm Session 2 “USP<800> COMPLIANCE IN LTC: TOO HAZARDOUS TO HANDLE?” Speaker, Erin Marriott, PharmD
1:10pm to 1:20pm Break
1:20pm to 2:20pm Session 3 “Prevention of Medication Errors” Speaker, Wendy Kallaher, RN
Schedule:
Safety in Numbers
1. Discuss the aging of America and the impact of changes in demographics on the long-term care industry. 2. Describe changes in acuity and comorbidity of older adults and how medication use, and management will change in the next 5-10 years. 3. Discuss health care by evolving technology that will influence at-home, assisted living and skilled nursing care. 4. Describe what the future of long term care might look like with all of the varied influence like staffing, technology, and medication management.
Chad Worz
Levodopa and Beyond - Advances in the Treatment of Parkinson’s Disease
• Describe the pathophysiology and presentation of Parkinson's Disease • List common motor and non-motor symptoms of Parkinson’s Disease • Differentiate the pharmacology and adverse effects of various treatments that address the motor dysfunction of Parkinson’s Disease • Recognize when to recommend treatment changes as patients progress through the stages of Parkinson’s Disease
Dana Saffel
Addressing the Expanding Use of Psychotropic Medications in Long-Term Care Settings
1. Recognize psychotropic medications and other medications that may share CMS psychotropic medication requirements 2. Describe CMS regulations regarding the use of psychotropic medications in the long-term care setting 3. Evaluate appropriate methods for monitoring psychotropic medications 4. Discuss the FDA approval for an antipsychotic medication for the treatment of agitation associated with dementia due to Alzheimer disease 5. Describe key elements of antipsychotic stewardship in long-term care settings
Darla Spears
Drug Diversion
James Almond
USP<800> Compliance in LTC
Erin Marriott
Prevention of Medication Errors
Wendy Kallaher
